Human Adipose-Derived Mesenchymal Stromal Cells Exhibit High HLA-DR Levels and Altered Cellular Characteristics under a Xeno-free and Serum-free Condition

Abstract

Background We have observed an increased expression of negative markers in some clinical-grade, xeno- and serum-free cultured adipose-derived mesenchymal stem/stromal cell (ADMSC) samples. It gave rise to concern that xeno- and serum-free conditions might have unexpected effects on human ADMSCs. This study aims to test this hypothesis for two xeno- and serum-free media, PowerStem MSC1 media (PS) and StemMACS MSC Expansion Media (SM), that support the in vitro expansion of ADMSCs. Methods We investigated the expression of negative markers in 42 clinical-grade ADMSC samples expanded in PS. Next, we cultured ADMSCs from seven donors in PS and SM and examined their growth and colony-forming ability, surface marker expression, differentiation, cell cycle and senescence, as well as genetic stability of two passages representing an early and late passage for therapeutic MSCs. Results 15 of 42 clinical-grade PS-expanded ADMSC samples showed an increased expression of negative markers ranging from 2.73% to 34.24%, which positively correlated with the age of donors. This rise of negative markers was related to an upregulation of Human Leukocyte Antigen – DR (HLA-DR). In addition, the PS-cultured cells presented decreased growth ability, lower frequencies of cells in S/G2/M phases, and increased ß-galactosidase activity in passage 7 suggesting their senescent feature compared to those grown in SM. Although MSCs of both PS and SM cultures were capable of multilineage differentiation, the PS-cultured cells demonstrated chromosomal abnormalities in passage 7 compared to the normal karyotype of their SM counterparts. Conclusions These findings suggest that the SM media is more suitable for the expansion of therapeutic ADMSCs than PS. The study also hints a change of ADMSC features at more advanced passages and with increased donor’s age. Thus, it emphasizes the necessity to cover these aspects in the quality control of therapeutic MSC products. Graphical abstract

Adipose-Derived Stromal Cells for Chronic Wounds: Scientific Evidence and Roadmap Toward Clinical Practice

“…ASCs, and mesenchymal stem cells in general, have long been considered hypoimmunogenic because of the absence of HLA class II, low expression of HLA class I and co-stimulatory molecules such as CD40 and CD80. However, some studies have highlighted that ASCs can become more immunogenic during cell expansion in vitro, depending on culture conditions, 67 , 68 and may induce cellular and humoral responses when used in an allogeneic setting. 69 , 70 Complement activation properties have also been reported.…”

Sodium selenite preserves rBM-MSCs’ stemness, differentiation potential, and immunophenotype and protects them against oxidative stress via activation of the Nrf2 signaling pathway

“…Subsequently, the CD markers profile of rBM-MSCs were checked using flow cytometry. There are some reports regarding aged-associated lessening of CD markers profile [ 104 , 105 ]. Moreover, some publications reported that MSCs surface markers decrease in higher passages [ 106 ] which subsequently, reduces the stemness and differentiation capacity and as a result, decreases the quality of MSCs.…”

A Small-Molecule Cocktails-Based Strategy in Culture of Mesenchymal Stem Cells

“…HLA-DR belongs to the major histocompatibility complex class II and plays a crucial role in host immune responses. Previous reports suggest that HLA-DR could change the karyotypes and cause earlier senescence of MSCs ( Dam et al, 2021 ). Additionally, HLA-DR-expressing MSCs may increase the risk of an alloimmune response ( Kot et al, 2019 ).…”